Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | DRD4 | P21917 | 4/20 | 0.43 |
| ▸ | DRD3 | P35462 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071882 | 0.95 | CYP19A1 (0.45) | CYP19A1HPGDSIGMAR1CYP1A2SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL8834496 | 0.91 | CYP2C9 (0.41) | CYP19A1HPGDSIGMAR1CYP1A2SMN1; SMN2 | |
| SCHEMBL5795346 | 0.86 | KDM1A (0.48) | HPGDSMN1; SMN2DRD2DRD4DRD3 | |
| Trifluoroacetic Acid SCHEMBL8835060 | 0.83 | CYP2C9 (0.47) | HPGDDRD2DRD4DRD3HTR2A | |
| Trifluoroacetic Acid SCHEMBL8835033 | 0.80 | PKM (0.40) | CYP19A1HPGDSIGMAR1CYP1A2MEN1 | |
| SCHEMBL795210 | 0.79 | HPGD (0.68) | CYP19A1HPGDCYP1A2SMN1; SMN2KLKB1 | |
| SCHEMBL17283083 | 0.77 | PFKFB3 (0.58) | CYP19A1HPGDCYP1A2SMN1; SMN2KLKB1 | |
| SCHEMBL15924211 | 0.76 | HPGD (0.60) | CYP19A1HPGDCYP1A2SMN1; SMN2KLKB1 | |
| SCHEMBL15936871 | 0.76 | CYP19A1 (0.74) | CYP19A1HPGDCYP1A2SMN1; SMN2 | |
| SCHEMBL21332831 | 0.74 | HPGD (0.54) | CYP19A1HPGDCYP1A2SMN1; SMN2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | claimed |
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | CYP19A1 2652/4885HPGD 1291/4885SIGMAR1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.